Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 4/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345487 | 1.00 | CTSD (0.45) | CTSDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10151208 | 0.78 | PSEN1 (0.50) | CTSDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8240500 | 0.74 | CTSK (0.64) | CTSDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL345676 | 0.74 | CTSK (0.64) | CTSDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL28961339 | 0.74 | CTSD (0.67) | CTSDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL11661865 | 0.74 | CTSD (0.67) | CTSDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL345418 | 0.73 | CTSS (0.45) | CTSDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10151192 | 0.73 | CTSS (0.45) | CTSDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24050003 | 0.69 | CTSS (0.66) | CTSDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23080079 | 0.69 | PSENEN (0.48) | CTSDPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338471-B2 | (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2012-12-25 | — | — | US | disclosed |
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2012-01-19 | — | — | US | disclosed |
| US-8022092-B2 | (2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2009-08-27 | — | — | US | disclosed |
| WO-2007068474-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | CTSD 315/4885PSEN1 3046/4885PSEN2 2978/4885 |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | CTSD 315/4885PSEN1 3046/4885PSEN2 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.